Rush Medical Center Home Page Information for healthcare Professionals Rush University
FIND A DOCTOR
PATIENT & VISTOR SERVICES
HEALTH INFORMATION
CLINICAL SERVICES
EVENTS & CLASSES
RUSH NEWS ROOM
CLINICAL TRIALS
RESEARCH AT RUSH
NURSING AT RUSH
WORK AT RUSH
GIVING TO RUSH

Bookmark This Page
Clinical Trails at Rush Antihypertensive Treatment of Cerebral Hemorrhage (ATACH-II)
Clinical Trial Protocol ID
11051303

Clinical Trial Investigator Name
Rajeev Garg

Clinical Trial Title

Antihypertensive Treatment of Cerebral Hemorrhage (ATACH-II)



Clinical Trial Protocol Description

An estimated 37,000 to 52,000 people in the United States have intracerebral hemorrhage (ICH) every year. Elevated blood pressure (BP) is observed in 46 to 75 percent of patients with ICH, and a variety of BP protocols are in place for treatment but lack appropriate evidence. Hematoma expansion is a common and important cause of poor outcome and elevated BP may predispose to hematoma expansion. Experimental clinical studies suggest reduction of elevated BP may be tolerated and feasible.

ATACH-II is a phase III, randomized, multicenter, concurrently controlled, parallel arms design clinical trial examining blood pressure reduction for hypertension in acute ICH. It will determine the therapeutic benefit of intensive SBP treatment using IV nicardipine (SBP≤140) compared with standard SBP treatment (SBP≤180) in reducing the proportion of patients with death and disability in subjects with ICH treated within 3.5 hours.



Clinical Trial Eligibility Criteria

You may be eligible to participate in this study if you:

  • Are an adult over 18 years of age
  • Exhibit clinical signs consistent with diagnosis of stroke, including impairment of language, motor function, cognition, and/or gaze, vision or neglect
  • Can receive IV Nicardipine within 3.5 hours of symptom onset
  • Can be randomized within 3.5 hours of symptom onset

You will be excluded from this study if you:

  • Have ICH due to previously known neoplasms, AVM or aneurysms
  • Have intracerebral hematoma considered to be related to trauma
  • Are to receive immediate surgical evacuation

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.





Contact Name Fumie Kita
Contact Phone (312) 942-2706
Contact E-mail Rush_Stroke @rush.edu
Promotional Information

Clinical Trials Home
Neurological Disorders Trials
Antihypertensive Treatment of Cerebral Hemorrhage (ATACH-II)

   
Find a Doctor | Patient & Visitor Services | Health Information
Clinical Services | Events & Classes | Rush News Room | Clinical Trials
Research At Rush
Disclaimer | Privacy Statement | Site Map

© Rush University Medical Center, Chicago, Illinois